scholarly journals Drug–Target Kinetics in Drug Discovery

2017 ◽  
Vol 9 (1) ◽  
pp. 29-39 ◽  
Author(s):  
Peter J. Tonge
Keyword(s):  
Drug Discovery ◽  
Drug Target

Use of Molecular Dynamics Simulations in Structure-Based Drug Discovery

2019 ◽  
Vol 25 (31) ◽  
pp. 3339-3349 ◽  
Author(s):  
Indrani Bera ◽  
Pavan V. Payghan
Keyword(s):  
Molecular Dynamics ◽  
Drug Discovery ◽  
Molecular Dynamics Simulations ◽  
Drug Target ◽  
Structural Information ◽  
Drug Binding ◽  
Structure Based Drug Design ◽  
Drug Designing ◽  
Target Binding ◽  
Dynamics Simulations

Background: Traditional drug discovery is a lengthy process which involves a huge amount of resources. Modern-day drug discovers various multidisciplinary approaches amongst which, computational ligand and structure-based drug designing methods contribute significantly. Structure-based drug designing techniques require the knowledge of structural information of drug target and drug-target complexes. Proper understanding of drug-target binding requires the flexibility of both ligand and receptor to be incorporated. Molecular docking refers to the static picture of the drug-target complex(es). Molecular dynamics, on the other hand, introduces flexibility to understand the drug binding process. Objective: The aim of the present study is to provide a systematic review on the usage of molecular dynamics simulations to aid the process of structure-based drug design. Method: This review discussed findings from various research articles and review papers on the use of molecular dynamics in drug discovery. All efforts highlight the practical grounds for which molecular dynamics simulations are used in drug designing program. In summary, various aspects of the use of molecular dynamics simulations that underline the basis of studying drug-target complexes were thoroughly explained. Results: This review is the result of reviewing more than a hundred papers. It summarizes various problems that use molecular dynamics simulations. Conclusion: The findings of this review highlight how molecular dynamics simulations have been successfully implemented to study the structure-function details of specific drug-target complexes. It also identifies the key areas such as stability of drug-target complexes, ligand binding kinetics and identification of allosteric sites which have been elucidated using molecular dynamics simulations.

scholarly journals Open-source chemogenomic data-driven algorithms for predicting drug–target interactions

2018 ◽  
Vol 20 (4) ◽  
pp. 1465-1474 ◽  
Author(s):  
Ming Hao ◽  
Stephen H Bryant ◽  
Yanli Wang
Keyword(s):  
Drug Discovery ◽  
Human Genome ◽  
High Throughput Screening ◽  
Drug Target ◽  
Drug Targets ◽  
Drug Repositioning ◽  
Research Field ◽  
Data Driven ◽  
Source Codes ◽  
Novel Technologies

AbstractWhile novel technologies such as high-throughput screening have advanced together with significant investment by pharmaceutical companies during the past decades, the success rate for drug development has not yet been improved prompting researchers looking for new strategies of drug discovery. Drug repositioning is a potential approach to solve this dilemma. However, experimental identification and validation of potential drug targets encoded by the human genome is both costly and time-consuming. Therefore, effective computational approaches have been proposed to facilitate drug repositioning, which have proved to be successful in drug discovery. Doubtlessly, the availability of open-accessible data from basic chemical biology research and the success of human genome sequencing are crucial to develop effective in silico drug repositioning methods allowing the identification of potential targets for existing drugs. In this work, we review several chemogenomic data-driven computational algorithms with source codes publicly accessible for predicting drug–target interactions (DTIs). We organize these algorithms by model properties and model evolutionary relationships. We re-implemented five representative algorithms in R programming language, and compared these algorithms by means of mean percentile ranking, a new recall-based evaluation metric in the DTI prediction research field. We anticipate that this review will be objective and helpful to researchers who would like to further improve existing algorithms or need to choose appropriate algorithms to infer potential DTIs in the projects. The source codes for DTI predictions are available at: https://github.com/minghao2016/chemogenomicAlg4DTIpred.

COMPUTATIONAL APPROACHES FOR DRUG DISCOVERY FROM MEDICINAL PLANTS IN THE ERA OF DATA DRIVEN RESEARCH

INDIAN DRUGS ◽  
2021 ◽  
Vol 58 (08) ◽  
pp. 7-23
Author(s):  
Pratibha Pansari ◽  
Keyword(s):  
Drug Discovery ◽  
Medicinal Plants ◽  
In Silico ◽  
Drug Target ◽  
Target Gene ◽  
Scientific Work ◽  
Data Driven ◽  
Network Pharmacology ◽  
Gene Pathway ◽  
Topological Network

The significant scientific work on the development of bio-active compound databases, computational technologies, and the integration of Information Technology with Biotechnology has brought a revolution in the domain of drug discovery. These tools facilitate the medicinal plant-based in silico drug discovery, which has become the frontier of pharmacological science. In this review article, we elucidate the methodology of in silico drug discovery for the medicinal plants and present an outlook on recent tools and technologies. Further, we explore the multi-component, multi-target, and multi-pathway mechanism of the bio-active compounds with the help of Network Pharmacology, which enables us to create a topological network between drug, target, gene, pathway, and disease.

scholarly journals Turning a Drug Target into a Drug Candidate: A New Paradigm for Neurological Drug Discovery?

BioEssays ◽  
2020 ◽  
Vol 42 (9) ◽  
pp. 2000011
Author(s):  
Steven D. Buckingham ◽  
Harry‐Jack Mann ◽  
Olivia K. Hearnden ◽  
David B. Sattelle
Keyword(s):  
Drug Discovery ◽  
Drug Target ◽  
Drug Candidate ◽  
New Paradigm

scholarly journals Unbiased Identification of Extracellular Protein–Protein Interactions for Drug Target and Biologic Drug Discovery

2021 ◽  
Author(s):  
Shengya Cao ◽  
Nadia Martinez-Martin
Keyword(s):  
Drug Discovery ◽  
Protein Interactions ◽  
Drug Target ◽  
Drug Targets ◽  
Extracellular Protein ◽  
Protein Protein Interactions ◽  
Cellular Functions ◽  
Drug Target Discovery ◽  
Technological Improvements ◽  
Targeted Drug Discovery

Technological improvements in unbiased screening have accelerated drug target discovery. In particular, membrane-embedded and secreted proteins have gained attention because of their ability to orchestrate intercellular communication. Dysregulation of their extracellular protein–protein interactions (ePPIs) underlies the initiation and progression of many human diseases. Practically, ePPIs are also accessible for modulation by therapeutics since they operate outside of the plasma membrane. Therefore, it is unsurprising that while these proteins make up about 30% of human genes, they encompass the majority of drug targets approved by the FDA. Even so, most secreted and membrane proteins remain uncharacterized in terms of binding partners and cellular functions. To address this, a number of approaches have been developed to overcome challenges associated with membrane protein biology and ePPI discovery. This chapter will cover recent advances that use high-throughput methods to move towards the generation of a comprehensive network of ePPIs in humans for future targeted drug discovery.

scholarly journals Golgi Recruitment Assay for Visualizing Small-Molecule Ligand–target Engagement in Cells

2020 ◽  
Author(s):  
Sachio Suzuki ◽  
Masahiro Ikuta ◽  
Tatsuyuki Yoshii ◽  
Akinobu Nakamura ◽  
Keiko Kuwata ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Ligand Binding ◽  
Drug Target ◽  
Chemical Biology ◽  
Protein Isoforms ◽  
Target Engagement ◽  
Ligand Affinity ◽  
Important Challenge ◽  
Small Molecule Ligand ◽  
In Cells

<b>The development of methods that allow detection of ligand–target engagement in cells is an important challenge in chemical biology and drug discovery. Here, we present a Golgi recruitment (G-REC) assay in which the ligand binding to the target protein can be visualized as Golgi-localized fluorescence signals. We show that the G-REC assay is applicable to the detection of various ligand–target interactions, ligand affinity comparison among distinct protein isoforms, and the monitoring of unmodified drug–target engagement in cells.</b>

scholarly journals DTI-SNNFRA: Drug-target interaction prediction by shared nearest neighbors and fuzzy-rough approximation

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246920
Author(s):  
Sk Mazharul Islam ◽  
Sk Md Mosaddek Hossain ◽  
Sumanta Ray
Keyword(s):  
Drug Discovery ◽  
Drug Target ◽  
Drug Repositioning ◽  
Geometric Mean ◽  
Imbalanced Data ◽  
Drug Repurposing ◽  
Search Space ◽  
Classification Model ◽  
Target Interaction ◽  
Rough Approximation

In-silico prediction of repurposable drugs is an effective drug discovery strategy that supplements de-nevo drug discovery from scratch. Reduced development time, less cost and absence of severe side effects are significant advantages of using drug repositioning. Most recent and most advanced artificial intelligence (AI) approaches have boosted drug repurposing in terms of throughput and accuracy enormously. However, with the growing number of drugs, targets and their massive interactions produce imbalanced data which may not be suitable as input to the classification model directly. Here, we have proposed DTI-SNNFRA, a framework for predicting drug-target interaction (DTI), based on shared nearest neighbour (SNN) and fuzzy-rough approximation (FRA). It uses sampling techniques to collectively reduce the vast search space covering the available drugs, targets and millions of interactions between them. DTI-SNNFRA operates in two stages: first, it uses SNN followed by a partitioning clustering for sampling the search space. Next, it computes the degree of fuzzy-rough approximations and proper degree threshold selection for the negative samples’ undersampling from all possible interaction pairs between drugs and targets obtained in the first stage. Finally, classification is performed using the positive and selected negative samples. We have evaluated the efficacy of DTI-SNNFRA using AUC (Area under ROC Curve), Geometric Mean, and F1 Score. The model performs exceptionally well with a high prediction score of 0.95 for ROC-AUC. The predicted drug-target interactions are validated through an existing drug-target database (Connectivity Map (Cmap)).

scholarly journals In silico analysis of alternative splicing on drug-target gene interactions

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yanrong Ji ◽  
Rama K. Mishra ◽  
Ramana V. Davuluri
Keyword(s):  
Alternative Splicing ◽  
Drug Discovery ◽  
Drug Target ◽  
In Silico Analysis ◽  
Binding Pocket ◽  
Protein Isoforms ◽  
Cancer Drug ◽  
Discovery Research ◽  
Structure Level ◽  
Drug Discovery Research

AbstractIdentifying and evaluating the right target are the most important factors in early drug discovery phase. Most studies focus on one protein ignoring the multiple splice-variant or protein-isoforms, which might contribute to unexpected therapeutic activity or adverse side effects. Here, we present computational analysis of cancer drug-target interactions affected by alternative splicing. By integrating information from publicly available databases, we curated 883 FDA approved or investigational stage small molecule cancer drugs that target 1,434 different genes, with an average of 5.22 protein isoforms per gene. Of these, 618 genes have ≥5 annotated protein-isoforms. By analyzing the interactions with binding pocket information, we found that 76% of drugs either miss a potential target isoform or target other isoforms with varied expression in multiple normal tissues. We present sequence and structure level alignments at isoform-level and make this information publicly available for all the curated drugs. Structure-level analysis showed ligand binding pocket architectures differences in size, shape and electrostatic parameters between isoforms. Our results emphasize how potentially important isoform-level interactions could be missed by solely focusing on the canonical isoform, and suggest that on- and off-target effects at isoform-level should be investigated to enhance the productivity of drug-discovery research.

Sign in / Sign up

Export Citation Format

Share Document